CLEAN BRIEFING DOCS
Sneeze breeze? No FDA ragweed quibbles for Merck, Alk-Abello
By Randy Osborne
Briefing papers for the meeting next week of the FDA’s Allergenic Products Advisory Committee suggest that the panel will green-light the sublingual ragweed allergy therapy from Alk-Abello A/S and Merck and Co. Inc., just as the grass-pollen allergy tablet sailed through last month.